Intuitive Surgical Intrinsic Value Calculation – INTUITIVE SURGICAL Reports Record Revenue and Net Income for FY2023 Q2
July 22, 2023
🌥️Earnings Overview
INTUITIVE SURGICAL ($NASDAQ:ISRG) reported FY2023 Q2 total revenue of USD 1755.9 million and net income of USD 420.8 million, ending on June 30 2023. This marked a 15.4% year-over-year revenue increase and a 36.7% rise in net income.
Stock Price
The company’s stock opened at $350.0 and closed at $347.7, down 0.6% from the prior closing price of $349.7. The increase in net income was driven by higher procedure volumes and higher average selling prices compared to the prior year quarter. Additionally, the company also benefited from strong contributions from its da Vinci X and SP robotic systems, which helped to drive the growth in revenue and net income. Overall, INTUITIVE SURGICAL‘s second quarter results suggest that the company is continuing to capitalize on its market leadership position in robotic-assisted surgery and are reflected in the slight decrease in stock price despite record revenue and net income. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intuitive Surgical. More…
| Total Revenues | Net Income | Net Margin |
| 6.66k | 1.43k | 21.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intuitive Surgical. More…
| Operations | Investing | Financing |
| 1.64k | 1.37k | -2.57k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.9k | 1.94k | 32.01 |
Key Ratios Snapshot
Some of the financial key ratios for Intuitive Surgical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.2% | 12.9% | 24.3% |
| FCF Margin | ROE | ROA |
| 15.1% | 9.0% | 7.3% |
Analysis – Intuitive Surgical Intrinsic Value Calculation
At GoodWhale, we have performed an analysis of INTUITIVE SURGICAL‘s financials. Through our proprietary Valuation Line, we have determined that the fair value of INTUITIVE SURGICAL’s share is around $319.2. Currently, INTUITIVE SURGICAL stock is traded at $347.7, which is a fair price that is overvalued by 8.9%. More…
Peers
The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.
– Stryker Corp ($NYSE:SYK)
With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.
– Medtronic PLC ($NYSE:MDT)
Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.
– Becton, Dickinson and Co ($NYSE:BDX)
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.
Summary
INTUITIVE SURGICAL experienced impressive financial growth in their second quarter of FY2023 ending June 30th, with total revenue increasing 15.4%, and net income increasing 36.7%. This strong performance makes INTUITIVE SURGICAL an attractive investment option for those looking for a reliable, high-growth company. Analysts have suggested that the company’s growing presence in the surgical robotics field is driving its success, with its da Vinci surgical system leading the market in robotic-assisted surgery. With a positive outlook for the remainder of FY2023 and beyond, now is a great time to consider investing in INTUITIVE SURGICAL.
